Abstract |
Ceftazidime was administered to 41 patients with serious infections caused by Pseudomonas aeruginosa (24 cases) and other bacteria (17 cases). The clinical response rate of pseudomonas infections (88%) was similar to that of other bacteria (94%) with microbiological eradication of 83% of initial pseudomonas isolates compared to 82% of non-pseudomonas strains. The development of resistance to ceftazidime during therapy was observed in 3 cases (Enterobacter agglomerans, Enterobacter cloacae, and Ps. aeruginosa), and superinfection by a resistant Enterobacter agglomerans occurred in one case. Adverse reactions of clinical significance included two cases of leukopenia and one case each of azotaemia, diarrhoea (Clostridium difficile toxin positive), and rash.
|
Authors | L J Eron, C H Park, D L Hixon, R I Goldenberg, D M Poretz |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 12 Suppl A
Pg. 161-9
(Jul 1983)
ISSN: 0305-7453 [Print] England |
PMID | 6225762
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Cephalosporins
- Ceftazidime
|
Topics |
- Abscess
(drug therapy)
- Adolescent
- Adult
- Aged
- Ceftazidime
- Cephalosporins
(adverse effects, therapeutic use)
- Diarrhea
(chemically induced)
- Drug Eruptions
(etiology)
- Drug Resistance, Microbial
- Female
- Humans
- Leukopenia
(chemically induced)
- Male
- Middle Aged
- Osteomyelitis
(drug therapy)
- Pseudomonas Infections
(drug therapy)
- Respiratory Tract Infections
(drug therapy)
- Skin Diseases, Infectious
(drug therapy)
- Uremia
(chemically induced)
|